Menu Search
Equities

Cardiol Therapeutics Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
CT9:MUN

Cardiol Therapeutics Inc

Actions
  • Price (EUR)0.832
  • Today's Change-0.015 / -1.77%
  • Shares traded3.00k
  • 1 Year change-39.00%
  • Beta0.6951
Data delayed at least 15 minutes, as of Feb 06 2026 07:01 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Cardiol Therapeutics Inc. is a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The Company is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.

  • Revenue in CAD (TTM)0.00
  • Net income in CAD-34.78m
  • Incorporated2017
  • Employees18.00
  • Location
    Cardiol Therapeutics Inc602-2265 Upper Middle Road EastOAKVILLE L6H 0G5CanadaCAN
  • Phone+1 (289) 910-0850
  • Fax+1 (905) 491-6793
  • Websitehttps://www.cardiolrx.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.